KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Net Margin (2016 - 2025)

Teva Pharmaceutical Industries' Net Margin history spans 10 years, with the latest figure at 9.89% for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 1962.0% year-over-year to 9.89%, compared with a TTM value of 8.0% through Dec 2025, up 2610.0%, and an annual FY2025 reading of 8.11%, up 2000.0% over the prior year.
  • Net Margin for Q4 2025 was 9.89% at Teva Pharmaceutical Industries, up from 9.55% in the prior quarter.
  • The five-year high for Net Margin was 9.89% in Q4 2025, with the low at 54.79% in Q4 2022.
  • Average Net Margin over 5 years is 18.17%, with a median of 18.46% recorded in 2022.
  • Biggest YoY gain for Net Margin was 9188bps in 2021; the steepest drop was -3061bps in 2021.
  • Tracing TEVA's Net Margin over 5 years: stood at 27.24% in 2021, then crashed by -101bps to 54.79% in 2022, then surged by 94bps to 3.46% in 2023, then crashed by -181bps to 9.72% in 2024, then skyrocketed by 202bps to 9.89% in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Net Margin are 9.89% (Q4 2025), 9.55% (Q3 2025), and 6.56% (Q2 2025).